fenofibrate has been researched along with Biliary Cirrhosis in 29 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the efficacy of fenofibrate combination therapy in Chinese patients with primary biliary cirrhosis (PBC) who had a partial response to standard dose of ursodeoxycholic acid (UDCA) for at least one year." | 9.16 | Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy. ( Bian, ZL; Han, XF; Liu, Y; Ma, X; Qiu, DK; Wang, QX; You, ZR, 2012) |
| "Fenofibrate is a potential novel therapy for primary biliary cirrhosis (PBC)." | 8.91 | Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis. ( Corpechot, C; Grigorian, AY; Levy, C; Mardini, HE; Poupon, R, 2015) |
| "Although the effectiveness of treatment with ursodeoxycholic acid (UDCA) and fenofibrate for primary biliary cirrhosis (PBC) has been suggested by small trials, a systematic review to summarize the evidence has not yet been carried out." | 8.91 | Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis. ( Chen, K; Guo, C; He, L; Li, J; Li, S; Liu, T; Lu, J; Lu, W; Wang, F; Wang, J; Xia, Y; Yin, Q; Zhang, Y; Zheng, Y; Zhou, Y, 2015) |
| "primary biliary cholangitis (PBC) patients with a suboptimal response to ursodeoxycholic acid (UDCA) have a significantly worse survival rate." | 7.88 | Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA. ( Duan, W; Jia, J; Ma, H; Ou, X; Wang, Q; Wang, X; Wang, Y; Wu, X; You, H; Zhang, W; Zhao, X, 2018) |
| "Ursodeoxycholic acid (UDCA) is currently the only available pharmacological treatment for asymptomatic primary biliary cirrhosis (aPBC)." | 7.79 | Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis. ( Dohmen, K; Haruno, M; Tanaka, H, 2013) |
| "To evaluate the efficacy and safety of fenofibrate in patients with primary biliary cirrhosis and incomplete response to UDCA." | 7.77 | Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. ( Cabrera, R; Clark, V; Firpi, RJ; Keach, J; Levy, C; Lindor, K; Morelli, G; Nelson, DR; Peter, JA; Petz, J; Soldevila-Pico, C, 2011) |
| "Fenofibrate was administered for twelve weeks in nine patients with aPBC who failed to respond to UDCA." | 6.71 | Fenofibrate for patients with asymptomatic primary biliary cirrhosis. ( Dohmen, K; Ishibashi, H; Mizuta, T; Nakamuta, M; Shimohashi, N; Yamamoto, K, 2004) |
| "Adult patients with primary biliary cholangitis (PBC, n = 32) and primary sclerosing cholangitis (PSC, n = 23), who experienced an incomplete response while receiving ursodiol monotherapy (13-15 mg/kg/day), defined as serum alkaline phosphatase (ALP) ≥ 1." | 5.62 | Adjunct Fenofibrate Up-regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis. ( Assis, DN; Barbier, O; Boyer, JL; Gallucci, GM; Ghonem, NS; Hemme, C; Trottier, J, 2021) |
| "To investigate the efficacy of fenofibrate combination therapy in Chinese patients with primary biliary cirrhosis (PBC) who had a partial response to standard dose of ursodeoxycholic acid (UDCA) for at least one year." | 5.16 | Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy. ( Bian, ZL; Han, XF; Liu, Y; Ma, X; Qiu, DK; Wang, QX; You, ZR, 2012) |
| "Fenofibrate is a potential novel therapy for primary biliary cirrhosis (PBC)." | 4.91 | Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis. ( Corpechot, C; Grigorian, AY; Levy, C; Mardini, HE; Poupon, R, 2015) |
| "Although the effectiveness of treatment with ursodeoxycholic acid (UDCA) and fenofibrate for primary biliary cirrhosis (PBC) has been suggested by small trials, a systematic review to summarize the evidence has not yet been carried out." | 4.91 | Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis. ( Chen, K; Guo, C; He, L; Li, J; Li, S; Liu, T; Lu, J; Lu, W; Wang, F; Wang, J; Xia, Y; Yin, Q; Zhang, Y; Zheng, Y; Zhou, Y, 2015) |
| "primary biliary cholangitis (PBC) patients with a suboptimal response to ursodeoxycholic acid (UDCA) have a significantly worse survival rate." | 3.88 | Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA. ( Duan, W; Jia, J; Ma, H; Ou, X; Wang, Q; Wang, X; Wang, Y; Wu, X; You, H; Zhang, W; Zhao, X, 2018) |
| "Ursodeoxycholic acid (UDCA) is currently the only available pharmacological treatment for asymptomatic primary biliary cirrhosis (aPBC)." | 3.79 | Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis. ( Dohmen, K; Haruno, M; Tanaka, H, 2013) |
| "To evaluate the efficacy and safety of fenofibrate in patients with primary biliary cirrhosis and incomplete response to UDCA." | 3.77 | Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. ( Cabrera, R; Clark, V; Firpi, RJ; Keach, J; Levy, C; Lindor, K; Morelli, G; Nelson, DR; Peter, JA; Petz, J; Soldevila-Pico, C, 2011) |
| "Fenofibrate was administered for twelve weeks in nine patients with aPBC who failed to respond to UDCA." | 2.71 | Fenofibrate for patients with asymptomatic primary biliary cirrhosis. ( Dohmen, K; Ishibashi, H; Mizuta, T; Nakamuta, M; Shimohashi, N; Yamamoto, K, 2004) |
| "Obeticholic acid was approved for treatment as add-on therapy in this group of patients." | 2.58 | Current Treatment Options for Primary Biliary Cholangitis. ( Bahar, R; Bowlus, CL; Liu, CH; Wong, KA, 2018) |
| "Primary biliary cholangitis is an archetypal autoimmune disease that causes cholestasis, fibrosis, and liver failure." | 2.58 | Work in Progress: Drugs in Development. ( Hirschfield, GM; Webb, GJ, 2018) |
| "All patients with primary biliary cirrhosis (PBC) and abnormal liver biochemistry should be considered for specific therapy." | 2.53 | Novel Therapies on Primary Biliary Cirrhosis. ( Czul, F; Levy, C, 2016) |
| "Treatment with fenofibrate prior to LPS significantly decreased nuclear NF-κB p50 and p65 subunit binding by 49% and 31%, respectively." | 1.72 | Fenofibrate Downregulates NF-κB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary Cholangitis. ( Alsuwayt, B; Assis, DN; Auclair, AM; Boyer, JL; Gallucci, GM; Ghonem, NS, 2022) |
| "Fenofibrate (FF) has shown potential benefits in patients with primary biliary cholangitis (PBC) who have an incomplete response to ursodeoxycholic acid (UDCA)." | 1.72 | Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid. ( Deng, J; Ding, D; Guo, C; Guo, G; Han, Y; Jia, G; Liu, Y; Shang, Y; Sun, R; Wang, X; Zheng, L, 2022) |
| "Fenofibrate (FF) has been suggested as a second-line therapy for primary biliary cholangitis (PBC) with suboptimal response to ursodeoxycholic acid (UDCA)." | 1.72 | Fenofibrate improves GLOBE and UK-PBC scores and histological features in primary biliary cholangitis. ( Han, Y; Liu, Y; Sun, K; Tian, A; Wang, L; Zhang, M; Zhou, X, 2022) |
| "Adult patients with primary biliary cholangitis (PBC, n = 32) and primary sclerosing cholangitis (PSC, n = 23), who experienced an incomplete response while receiving ursodiol monotherapy (13-15 mg/kg/day), defined as serum alkaline phosphatase (ALP) ≥ 1." | 1.62 | Adjunct Fenofibrate Up-regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis. ( Assis, DN; Barbier, O; Boyer, JL; Gallucci, GM; Ghonem, NS; Hemme, C; Trottier, J, 2021) |
| "When fenofibrate was added to Ursodiol therapy there was a significant reduction and in some cases normalization of serum alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase abnormalities, as well as pro-inflammatory cytokines." | 1.56 | Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol. ( Assis, DN; Auclair, AM; Boyer, JL; de la Rosa Rodriguez, R; Gallucci, GM; Ghonem, NS; Hemme, CL, 2020) |
| "Fenofibrate was also associated with improved decompensation-free and transplant-free survival [hazard ratio (HR) 0." | 1.43 | Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. ( Cheung, AC; Feld, JJ; Hirschfield, GM; Janssen, HL; Kowgier, M; Lapointe-Shaw, L; Meza-Cardona, J, 2016) |
| "Fenofibrate (FF) has been suggested as a second-line agent in primary biliary cholangitis (PBC) patients who do not achieve adequate biochemical response to ursodeoxycholic acid (UDCA) monotherapy." | 1.43 | Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score. ( Dyson, JK; Hegade, VS; Jones, DEJ; Khanna, A; Walker, LJ; Wong, LL, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (13.79) | 29.6817 |
| 2010's | 16 (55.17) | 24.3611 |
| 2020's | 9 (31.03) | 2.80 |
| Authors | Studies |
|---|---|
| Gallucci, GM | 3 |
| Trottier, J | 1 |
| Hemme, C | 1 |
| Assis, DN | 3 |
| Boyer, JL | 3 |
| Barbier, O | 1 |
| Ghonem, NS | 3 |
| Dohmen, K | 4 |
| Onohara, SY | 1 |
| Harada, S | 1 |
| Alsuwayt, B | 1 |
| Auclair, AM | 2 |
| Ding, D | 2 |
| Guo, G | 3 |
| Liu, Y | 5 |
| Zheng, L | 3 |
| Jia, G | 3 |
| Deng, J | 3 |
| Sun, R | 3 |
| Wang, X | 4 |
| Guo, C | 3 |
| Shang, Y | 3 |
| Han, Y | 4 |
| Ren, P | 1 |
| Yang, C | 2 |
| Zhou, X | 2 |
| Cui, L | 1 |
| Hemme, CL | 1 |
| de la Rosa Rodriguez, R | 1 |
| Wang, L | 1 |
| Sun, K | 1 |
| Tian, A | 1 |
| Zhang, M | 1 |
| Reig, A | 1 |
| Álvarez-Navascués, C | 1 |
| Vergara, M | 1 |
| Gómez-Domínguez, E | 1 |
| Gallego-Moya, A | 1 |
| Pérez-Medrano, IM | 1 |
| Fábrega, E | 1 |
| Hernández-Guerra, M | 1 |
| Berenguer, M | 1 |
| Estevez, P | 1 |
| Arencibia, A | 1 |
| Morillas, RM | 1 |
| Horta, D | 1 |
| Albillos, A | 1 |
| Casado, M | 1 |
| De la Cruz, G | 1 |
| Fernandez-Bonilla, E | 1 |
| Molina, E | 1 |
| Hijona, L | 1 |
| Diago, M | 1 |
| Fernández-Rodriguez, CM | 1 |
| González-Santiago, JM | 1 |
| Sala, M | 1 |
| Gómez-Camarero, J | 1 |
| Romero-Gomez, M | 1 |
| Suárez, F | 1 |
| Vargas, V | 1 |
| Ferre-Aracil, C | 1 |
| Andrade, RJ | 1 |
| Chahri, N | 1 |
| Parés, A | 1 |
| Strassburg, CP | 1 |
| Duan, W | 1 |
| Ou, X | 1 |
| Wang, Y | 1 |
| Zhao, X | 1 |
| Wang, Q | 1 |
| Wu, X | 1 |
| Zhang, W | 1 |
| Ma, H | 1 |
| You, H | 1 |
| Jia, J | 1 |
| Wong, KA | 1 |
| Bahar, R | 1 |
| Liu, CH | 1 |
| Bowlus, CL | 1 |
| Webb, GJ | 1 |
| Hirschfield, GM | 2 |
| Corpechot, C | 2 |
| Chazouillères, O | 1 |
| Lemoinne, S | 1 |
| Rousseau, A | 1 |
| Chung, SW | 1 |
| Lee, JH | 1 |
| Kim, MA | 1 |
| Leem, G | 1 |
| Kim, SW | 1 |
| Chang, Y | 1 |
| Lee, HY | 1 |
| Yoon, JS | 1 |
| Park, JY | 1 |
| Lee, YB | 1 |
| Cho, EJ | 1 |
| Yu, SJ | 1 |
| Kim, YJ | 1 |
| Yoon, JH | 1 |
| Tanaka, H | 1 |
| Haruno, M | 1 |
| Grigorian, AY | 1 |
| Mardini, HE | 1 |
| Poupon, R | 1 |
| Levy, C | 3 |
| Zhang, Y | 1 |
| Li, S | 1 |
| He, L | 1 |
| Wang, F | 1 |
| Chen, K | 1 |
| Li, J | 1 |
| Liu, T | 1 |
| Zheng, Y | 1 |
| Wang, J | 1 |
| Lu, W | 1 |
| Zhou, Y | 2 |
| Yin, Q | 1 |
| Xia, Y | 1 |
| Lu, J | 1 |
| Cheung, AC | 2 |
| Lapointe-Shaw, L | 1 |
| Kowgier, M | 2 |
| Meza-Cardona, J | 1 |
| Janssen, HL | 1 |
| Feld, JJ | 2 |
| Czul, F | 1 |
| Jones, DE | 2 |
| Hansen, BE | 1 |
| Hegade, VS | 1 |
| Khanna, A | 1 |
| Walker, LJ | 2 |
| Wong, LL | 1 |
| Dyson, JK | 1 |
| Jones, DEJ | 1 |
| Newton, J | 1 |
| Bassendine, MF | 1 |
| Peter, JA | 1 |
| Nelson, DR | 1 |
| Keach, J | 1 |
| Petz, J | 1 |
| Cabrera, R | 1 |
| Clark, V | 1 |
| Firpi, RJ | 1 |
| Morelli, G | 1 |
| Soldevila-Pico, C | 1 |
| Lindor, K | 1 |
| Han, XF | 1 |
| Wang, QX | 1 |
| You, ZR | 1 |
| Bian, ZL | 1 |
| Qiu, DK | 1 |
| Ma, X | 1 |
| Ohira, H | 1 |
| Sato, Y | 1 |
| Ueno, T | 1 |
| Sata, M | 1 |
| Mizuta, T | 1 |
| Nakamuta, M | 1 |
| Shimohashi, N | 1 |
| Ishibashi, H | 2 |
| Yamamoto, K | 1 |
| Wen, CY | 1 |
| Nagaoka, S | 1 |
| Yano, K | 1 |
| Abiru, S | 1 |
| Ueki, T | 1 |
| Komori, A | 1 |
| Daikoku, M | 1 |
| Yatsuhashi, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter, Randomized, Double-blind Placebo Controlled Trial of Bezafibrate for the Treatment of Primary Biliary Cirrhosis in Patients With Incomplete Response to Ursodesoxycholic Acid Therapy.[NCT01654731] | Phase 3 | 100 participants (Actual) | Interventional | 2012-10-15 | Completed | ||
| Pilot Study of Fenofibrate for Primary Biliary Cirrhosis[NCT00575042] | Phase 2 | 20 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
We analyzed whether there was a difference in median ALP at 1 year compared to baseline values. (NCT00575042)
Timeframe: 1 year
| Intervention | U/L (Median) |
|---|---|
| Patients Before Treatment With Fenofibrate | 351 |
| Patients Treated With Fenofibrate | 175 |
6 reviews available for fenofibrate and Biliary Cirrhosis
| Article | Year |
|---|---|
[Modern treatment of primary biliary cholangitis].
Topics: Bezafibrate; Budesonide; Chenodeoxycholic Acid; Cohort Studies; Female; Fenofibrate; Humans; Liver C | 2018 |
Current Treatment Options for Primary Biliary Cholangitis.
Topics: Alkaline Phosphatase; Bezafibrate; Chenodeoxycholic Acid; Cholagogues and Choleretics; Comorbidity; | 2018 |
Work in Progress: Drugs in Development.
Topics: Abatacept; Acetates; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents | 2018 |
Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis.
Topics: Chemotherapy, Adjuvant; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Treatment Outcome | 2015 |
Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis.
Topics: Cholagogues and Choleretics; Drug Therapy, Combination; Fenofibrate; Humans; Hypolipidemic Agents; L | 2015 |
Novel Therapies on Primary Biliary Cirrhosis.
Topics: Abatacept; Anti-Retroviral Agents; Antibodies, Monoclonal, Humanized; Bezafibrate; Chenodeoxycholic | 2016 |
3 trials available for fenofibrate and Biliary Cirrhosis
| Article | Year |
|---|---|
Effectiveness of Fenofibrate in Treatment-Naive Patients With Primary Biliary Cholangitis: A Randomized Clinical Trial.
Topics: Cholagogues and Choleretics; Drug Therapy, Combination; Fenofibrate; Humans; Liver Cirrhosis, Biliar | 2023 |
Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy.
Topics: Asian People; Biomarkers; Cholagogues and Choleretics; Drug Therapy, Combination; Female; Fenofibrat | 2012 |
Fenofibrate for patients with asymptomatic primary biliary cirrhosis.
Topics: Adult; Aged; Cholagogues and Choleretics; Female; Fenofibrate; Humans; Hypolipidemic Agents; Liver C | 2004 |
20 other studies available for fenofibrate and Biliary Cirrhosis
| Article | Year |
|---|---|
Adjunct Fenofibrate Up-regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis.
Topics: Adult; Bile Acids and Salts; Cholangitis, Sclerosing; Cholestasis; Drug Therapy, Combination; Female | 2021 |
Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis.
Topics: Benzoxazoles; Butyrates; Fenofibrate; Humans; Hypolipidemic Agents; Liver Cirrhosis, Biliary; Ursode | 2021 |
Fenofibrate Downregulates NF-κB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary Cholangitis.
Topics: Adult; Anti-Inflammatory Agents; Cytokines; Fenofibrate; Humans; Interleukin-8; Lipopolysaccharides; | 2022 |
Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid.
Topics: Alkaline Phosphatase; Cholagogues and Choleretics; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Re | 2022 |
Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid.
Topics: Alkaline Phosphatase; Cholagogues and Choleretics; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Re | 2023 |
Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol.
Topics: Adult; Aged; Bile Acids and Salts; Biomarkers; Cholangitis, Sclerosing; Cytokines; Drug Therapy, Com | 2020 |
Fenofibrate improves GLOBE and UK-PBC scores and histological features in primary biliary cholangitis.
Topics: Cholagogues and Choleretics; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Retrospective Studies; U | 2022 |
Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study.
Topics: Bezafibrate; Chenodeoxycholic Acid; Female; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Male; Mid | 2021 |
Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.
Topics: Adult; Aged; Cholagogues and Choleretics; Cholangitis; Cohort Studies; Drug Therapy, Combination; Fe | 2018 |
Letter: reduction in projected mortality or need for liver transplantation associated with bezafibrate add-on in primary biliary cholangitis with incomplete UDCA response.
Topics: Bezafibrate; Cholangitis; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Liver Transplantation; Urso | 2019 |
Additional fibrate treatment in UDCA-refractory PBC patients.
Topics: Alkaline Phosphatase; Bezafibrate; Cholagogues and Choleretics; Drug Therapy, Combination; Female; F | 2019 |
Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
Topics: Adult; Aged; Asymptomatic Diseases; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Cohort S | 2013 |
Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.
Topics: Adult; Aged; Alkaline Phosphatase; Bilirubin; Cholagogues and Choleretics; Cohort Studies; Female; F | 2016 |
Editorial: fenofibrate as second-line therapy in high risk PBC--more answers or more questions?
Topics: Female; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Male; Ursodeoxycholic Acid | 2016 |
Editorial: fenofibrate as second-line therapy in high risk PBC--more answers or more questions? Authors' reply.
Topics: Female; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Male; Ursodeoxycholic Acid | 2016 |
Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
Topics: Alanine Transaminase; Alkaline Phosphatase; Bilirubin; Cholagogues and Choleretics; Cohort Studies; | 2016 |
Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
Topics: Alkaline Phosphatase; Bezafibrate; Cholagogues and Choleretics; Drug Synergism; Fenofibrate; Humans; | 2009 |
Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.
Topics: Adult; Aged; Cholagogues and Choleretics; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hy | 2011 |
Fenofibrate treatment in patients with primary biliary cirrhosis.
Topics: Cholagogues and Choleretics; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hypolipidemic A | 2002 |
Fenofibrate-induced liver injury.
Topics: Aged; Female; Fenofibrate; Humans; Liver; Liver Cirrhosis, Biliary; PPAR alpha; Ursodeoxycholic Acid | 2005 |